Core Viewpoint - Mega Uranium Ltd. successfully held its annual shareholder meeting, where all nominated directors were elected with significant shareholder support [1]. Group 1: Election Results - Brigitte Berneche received 128,524,924 votes (99.3%) in favor and 847,991 votes (0.7%) withheld [1]. - Albert Contardi garnered 124,874,603 votes (96.5%) in favor and 4,498,312 votes (3.5%) withheld [1]. - Asha Daniere achieved 128,587,619 votes (99.4%) in favor and 785,296 votes (0.6%) withheld [1]. - Larry Goldberg received 124,878,567 votes (96.5%) in favor and 4,494,348 votes (3.5%) withheld [1]. - Stewart Taylor obtained 124,971,762 votes (96.6%) in favor and 4,401,153 votes (3.4%) withheld [1]. Group 2: Auditor Appointment - Ernst & Young LLP was appointed as the company's auditors during the meeting [1]. Group 3: Company Overview - Mega Uranium Ltd. is based in Toronto and focuses on the Georgetown uranium property in Australia, along with a portfolio of equity investments in uranium-focused public and private companies [3].

Core Insights - Rapid7, Inc. announced the granting of inducement awards to employees and contractors of Kenzo Security, Inc. as part of its acquisition of Kenzo on March 26, 2026 [1] Group 1: Inducement Awards - Rapid7 granted a total of 467,945 restricted stock units (RSUs) to Kenzo employees and contractors [2] - Founders of Kenzo, Harish Singh and Partha Naidu, received an additional inducement award of 525,769 performance-based restricted stock units (PSUs) [2] Group 2: Vesting and Performance Conditions - The RSUs will vest in three equal parts over three years, contingent on continued employment [3] - PSUs will be earned over two annual performance periods starting January 1, 2027, based on Rapid7's achievement of specific revenue goals [3] Group 3: Approval and Compliance - The RSUs and PSUs were granted under Rapid7's 2015 Equity Incentive Plan and were approved by the Compensation Committee in accordance with Nasdaq regulations [4]

Core Insights - Vivani Medical, Inc. has successfully completed its first-in-human study LIBERATE-1 for the NPM-139 semaglutide implant, which is aimed at chronic weight management, with results expected by the end of 2026 [1][4][16] - The company has demonstrated over 20% sham-adjusted weight loss sustained for a full year with a single preclinical administration of the semaglutide implant [1][4][5] - Vivani's financial position is solid, with $41.5 million raised in gross proceeds from various financings, expected to support operations into mid-2027 [2][8] Company Developments - The company is advancing its NPM-139 semaglutide implant based on positive results from LIBERATE-1 and preclinical studies, with plans to initiate a Phase 1 clinical study in mid-2026 [5][6] - Vivani's CEO highlighted the unique features of their GLP-1 implant candidates, including the potential for annual dosing and the ability to quickly cease treatment if necessary [4] - Significant progress has been made in manufacturing capabilities, preparing for commercial-scale production [4] Financial Performance - As of December 31, 2025, Vivani reported cash and cash equivalents of $16.2 million, down from $18.4 million in 2024, primarily due to a net loss of $26.6 million [11][19] - Research and development expenses for Q4 2025 were $4.6 million, a 7% increase from $4.3 million in Q4 2024, attributed to staffing reductions and decreased use of outside services [12] - The net loss for the full year 2025 was $26.6 million, compared to $23.5 million in 2024, reflecting increased clinical trial and development expenses [19] Upcoming Milestones - The company anticipates the initiation of the Phase 1 feasibility study for NPM-139 in mid-2026, with data potentially available by the end of the year [4][6][16] - Plans are in place for a Phase 2 clinical study of NPM-139, pending results from the Phase 1 study and regulatory feedback [6]

Core Viewpoint - Nanobiotix, a late-stage clinical biotechnology company, is set to report its financial results for Q4 and full year 2025 on March 31, 2026, followed by a conference call on April 1, 2026, to discuss the results and business updates [1][2]. Company Overview - Nanobiotix is pioneering nanoparticle-based therapeutic approaches aimed at improving treatment outcomes for cancer and other major diseases [1][4]. - The company was incorporated in 2003, is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on Nasdaq since December 2020 [5]. - Nanobiotix holds over 30 patent families related to three nanotechnology platforms, focusing on oncology, bioavailability and biodistribution, and central nervous system disorders [5]. Upcoming Events - A conference call and webcast will take place on April 1, 2026, at 8:00 AM EDT / 2:00 PM CEST, where the CEO and CFO will review year-end results and provide updates on business activities [2]. - Participants are encouraged to submit questions in advance via email [3].

Core Insights - Stifel Financial Corp. reported selected operating results for February 28, 2026, highlighting key performance metrics and indicating that a direct correlation to earnings should not be assumed [1] Group 1: Financial Performance - Total client assets reached $557.714 billion, a 10% increase year-over-year from $506.475 billion [2] - Fee-based client assets increased by 16% year-over-year to $228.012 billion, up from $196.380 billion [2] - Private Client Group fee-based client assets also rose by 16% year-over-year to $199.191 billion, compared to $171.760 billion [2] - Bank loans, net, increased by 5% year-over-year to $22.348 billion from $21.201 billion [2] - Client money market and insured products decreased by 6% year-over-year to $26.030 billion from $27.737 billion [2] - Treasury deposits surged by 73% year-over-year to $9.584 billion from $5.557 billion [2] Group 2: Business Developments - The sale of Stifel Independent Advisors, LLC was completed on February 2, 2026, impacting the reported client assets [2][6] - Excluding the assets related to the sale, total client assets and fee-based client assets increased by 12% and 19% year-over-year, respectively, driven by equity market appreciation and strong advisor recruiting [2] - Despite market volatility, investment banking activity in the first quarter of 2026 is expected to increase by 30%–40% compared to the first quarter of 2025 [2]

Core Insights - AmpliTech Group, Inc. reported a significant revenue increase of approximately 165% year-over-year, reaching $25.2 million for fiscal year 2025, driven by demand for 5G and core RF products [2][9] - The company is strategically positioning itself in the 5G market, with expectations of improved gross margins as it transitions to high-volume business with established operators [3][6][9] Financial Performance - Revenue for fiscal year 2025 was $25.2 million, up from $9.5 million in 2024, marking a growth of 165% [2] - Gross profit increased to $6.0 million from $3.5 million, with a gross margin of 23.9% in 2025 compared to 36.7% in 2024 [3] - Operating expenses rose to $10.7 million from $7.9 million, while research and development expenses decreased to $2.7 million from $3.6 million [4] - Net loss improved to $7.0 million from $11.2 million, a reduction of approximately 38% [5] Market Position and Opportunities - The company is advancing its portfolio of O-RAN compliant radio systems, including the flagship Massive MIMO 64T64R product, which has received O-RAN compliance certification [6] - In March 2025, AmpliTech entered a non-binding letter of intent for the purchase of up to $78 million of its O-RAN radios, with approximately $5 million in funded purchase orders received as of March 23, 2026 [7] Liquidity and Capital Structure - As of December 31, 2025, AmpliTech held cash and cash equivalents of approximately $5.0 million and working capital of $10.2 million [8] - The company raised additional capital through a rights offering and a registered direct offering to support growth initiatives [8] Company Overview - AmpliTech Group, Inc. designs, develops, and manufactures advanced RF and microwave signal-processing components and systems for various applications, including satellite and 5G telecom [10]

Core Insights - Middlesex Water Company has appointed Mrs. Tatyana Kaplan as Vice President and Chief Accounting Officer effective March 26, 2026 [1][2] - Kaplan has extensive experience in regulated utility accounting and has previously worked at Veolia North America and Prudential Financial [2][3] - The company also announced the departure of Mr. Robert J. Capko from the Principal Accounting Officer position, who will continue as Corporate Controller [3] Company Overview - Middlesex Water Company is a leading investor-owned water and wastewater utility, serving over half a million people in New Jersey and Delaware [4] - The company emphasizes employee engagement, operational excellence, superior customer experience, infrastructure investment, and sustainable growth [4]

Core Insights - Vroom, Inc. reported significant improvements in its financial performance for the full year 2025, with an adjusted net loss reduction of 57% from $115 million in 2024 to $49 million in 2025, attributed to strategic investments and operational focus [5][9]. Financial Highlights - As of December 31, 2025, Vroom's tangible book value was $104.2 million, with total stockholders' equity at $116.6 million, excluding intangible assets of $12.4 million [3][9]. - The company had total available liquidity of $48.7 million, which included $10.4 million in cash and cash equivalents, $11.3 million from warehouse credit facilities, and $27.0 million from a delayed draw facility [4][9]. - For the fourth quarter of 2025, Vroom reported a net loss from continuing operations of $(11.5) million, compared to $(36.0) million for the same period in 2024 [9][10]. Revenue and Income Analysis - Interest income for the fourth quarter of 2025 was $43.9 million, down from $48.7 million in the same quarter of 2024, reflecting a decrease of 10.8% [11]. - Total noninterest income for the fourth quarter was $7.9 million, a slight decrease from $8.5 million in the previous year [10]. - The company experienced realized and unrealized losses, net of recoveries, of $23.5 million in the fourth quarter, compared to $32.0 million in the same quarter of 2024, indicating an improvement [12]. Expense Management - Total expenses for the fourth quarter of 2025 were $27.0 million, significantly reduced from $41.2 million in the same quarter of 2024, marking a decrease of 65.1% [10][12]. - Compensation and benefits expenses decreased by 15.9% to $16.8 million in the fourth quarter of 2025 compared to $20.6 million in the same period of 2024 [10][12]. Segment Performance - In the UACC segment, interest income for the fourth quarter of 2025 was $43.9 million, down 10.8% from $49.2 million in the fourth quarter of 2024 [11]. - The CarStory revenue for the fourth quarter of 2025 was $1.3 million, a decline of 53.0% from $2.8 million in the same quarter of 2024 [13].

Core Insights - CapsoVision, Inc. reported significant operational and strategic progress in 2025, including the expansion of CapsoCam Plus® adoption and advancements in AI-enabled analytics [3] - The company completed a $14 million private placement, reinforcing confidence in its long-term strategy and supporting product innovation [3][8] Financial Performance - Fourth quarter 2025 revenue reached $3.9 million, a 13% increase from Q4 2024, while full year 2025 revenue was $13.6 million, a 15% increase compared to 2024 [4][9] - Gross profit for Q4 2025 was $2.0 million, a 13% increase from Q4 2024, and full year gross profit was $7.2 million, a 12% increase from 2024 [5] - Operating expenses for Q4 2025 were $9.4 million, a $3.0 million increase from Q4 2024, primarily due to development costs related to new CMOS image sensors and clinical trial activities [6] - For the full year 2025, operating expenses totaled $32.7 million, a $6.4 million increase compared to 2024, driven by development and administrative expenses [7] Product Development and Regulatory Milestones - The company submitted a 510(k) application to the FDA for its AI-assisted module for CapsoCam Plus®, marking a significant regulatory milestone [9] - CapsoVision is in ongoing dialogue with the FDA regarding the development of its next-generation colon capsule and the CapsoCam UGI pancreas initiative [3] Market Expansion - New accounts grew by 16% in Q4 2025 compared to Q4 2024, and full year new accounts increased by 21% compared to 2024 [9] - As of December 31, 2025, CapsoCam Plus® was used by over 161,000 patients, indicating strong market adoption [9] Financial Position - As of December 31, 2025, cash and cash equivalents totaled $10.1 million, an increase from $9.3 million at the end of 2024 [7][16] - The company completed an IPO in July 2025, generating net proceeds of $23.4 million, which supports its ongoing operations and development efforts [8]

Core Viewpoint - Datacentrex, Inc. has initiated a public offering of its common stock and pre-funded warrants, intending to use the proceeds for working capital and general corporate purposes, with the offering subject to market conditions [1][2]. Group 1: Offering Details - The offering is being managed by Dominari Securities LLC as the sole placement agent and is conducted under an effective shelf registration statement declared by the SEC [2]. - A preliminary prospectus supplement and accompanying shelf prospectus will be filed with the SEC, providing detailed terms of the offering [2][3]. Group 2: Company Overview - Datacentrex operates in the digital infrastructure sector, focusing on Scrypt compute assets and strategic transactions in asset-backed businesses [5]. - The company primarily monetizes its compute through hashrate marketplace mechanisms and manages a treasury of digital assets and cash to preserve capital and support opportunistic deployment [5].